IBRXAnother day, another deadline
Rosen Law Firm is reminding ImmunityBio investors that the lead-plaintiff deadline in the securities class action is May 26, 2026. The class period in question runs from January 19 through March 24, 2026, which means this is still very much a live issue for anyone who bought shares during that stretch.
Why investors should care
Class-action notices are not exactly the stuff of fireworks, but they can keep a bad-news cloud parked over a stock. If you own IBRX, the headline here is that the legal overhang is still building, not fading — and that can matter when a name is already trying to convince the market it deserves the benefit of the doubt.
The fine print that matters
- The notice comes from Rosen Law Firm, which says it first filed the case
- It’s tied to purchases made during the January 19 to March 24 class period
- The key date now is the May 26 lead-plaintiff deadline
Big picture
This isn’t a game-changing corporate event, but it is another reminder that litigation can stick to a stock like glitter: annoying, persistent, and weirdly hard to shake. For ImmunityBio, the legal noise stays part of the story until the courts say otherwise.